Weight gain and metabolic abnormalities are serious side effects associated with the use of several second generation antipsychotics (SGA). The adipose tissue has been considered a direct SGA target involved in the development of these adverse effects. Recent studies, mainly using murine cells, have suggested that SGA increase both adipogenesis of preadipocytes and lipid accumulation in mature adipocytes. However, to date there has been little research comparing the effects of antipsychotics with different propensities to induce weight gain on human in vitro models of white adipose tissue neoformation and metabolism. The present study aimed to investigate the effects of antipsychotics either strongly associated with weight gain, such as the SGA clozapine and olanzapine, or not, such as the SGA ziprasidone and the classical antipsychotic haloperidol, on proliferation and adipocyte differentiation of human adipose-derived stem cells (ADSCs) and lipogenesis in human mature adipocytes. Whereas ziprasidone induced elevated levels of cell death during adipogenesis and could not be investigated further, we observed that clozapine, olanzapine and haloperidol had slight stimulatory effects on the transcriptional program of ADSCs adipogenesis. However, the observed changes in adipocyte-specific genes were not accompanied by a significant increase in triglyceride accumulation within differentiated adipocytes. Our data also showed that these three antipsychotics displayed inhibitory effects on the proliferation rates of undifferentiated ADSCs. Regarding mature adipocyte metabolism, we observed that olanzapine slightly inhibited insulin-stimulated lipogenesis at the highest concentration used, and haloperidol exerted the strongest inhibitory effects on both basal and insulinstimulated lipogenesis. Taken together, our results suggest that a direct and potent effect of clozapine and olanzapine on adipose tissue biology is not an important mechanism by which these SGA induce metabolic disturbances in humans. On the other hand, the haloperidol-mediated downregulation of the lipogenic capacity of human adipose tissue may be a possible mechanism contributing to its lower propensity to induce serious metabolic side effects.
Introduction
Second generation antipsychotic drugs (SGA) are considered to possess superior efficacy in treating both positive and negative symptoms of schizophrenia compared to first-generation antipsychotics (FGA) (e.g. haloperidol) (Bridler and Umbricht, 2003; Keefe et al., 2006) . In addition, these drugs are increasingly being prescribed for other psychiatric disorders, such as bipolar disorder, autism, and depression (McDougle et al., 2008; Papakostas and Shelton, 2008; Pfeifer et al., 2010) . However, major side effects of SGA, such as clozapine and olanzapine, are weight gain and associated metabolic abnormalities including hyperglycemia, insulin resistance, type II diabetes, dyslipidemias and cardiovascular diseases (Ananth and Kolli, 2005; Casey, 2005; Newcomer, 2007; Panagiotopoulos et al., 2009) .
Although the exact mechanisms involved in SGA-induced weight gain and metabolic abnormalities are not yet fully understood, several studies have proposed that these side effects may reflect the antagonist properties of these drugs on central nervous system pathways involved in the food intake or energy expenditure, such as histaminergic, serotoninergic/noradrenergic pathways (Deng et al., 2009; Han et al., 2008; Matsui-Sakata et al., 2005; Opgen-Rhein et al., 2010; Reynolds et al., 2002) . Other studies have also explored a direct effect of some SGA on the biology of peripheral tissues involved in body energy homeostasis, such as the adipose tissue.
Increased white adipose tissue mass associated with obesity may be the function of both, increased adipocyte size, due to lipid accumulation within fully differentiated adipocytes, and increased adipocyte number, due to proliferation and adipogenic differentiation of progenitor cells present in the adipose tissue (Spalding et al., 2008) . Recent reports have suggested that specific SGA can exert direct effects on mature rat adipocytes from visceral white adipose tissue, increasing lipogenesis and decreasing lipolysis to facilitate adipocyte lipid storage (Minet-Ringuet et al., 2007; Vestri et al., 2006) . In addition, it was proposed that the SGA clozapine and olanzapine stimulate adipogenesis of the murine preadipocyte cell line 3T3L1 (Yang et al., 2007; . However, there are very limited data concerning the effects of SGA on cells derived from human adipose tissue (Hemmrich et al., 2006; Pavan et al., 2009 ), remaining substantial uncertainties over these effects.
The present study aimed to extend the findings of prior studies and compared the effects of antipsychotics with different weight gain liabilities, such as the SGA clozapine and olanzapine and the FGA haloperidol, on proliferation and adipocyte differentiation of human adipose-derived stem cells (ADSCs), as well as lipogenesis in human mature adipocytes.
Material and methods

Adipocyte-derived stem cells (ADSCs) isolation and expansion
Liposuction aspirates from abdominal subcutaneous adipose tissue were obtained from 5 health female subjects (aged 24-38 years; BMI b 25 kg/m 2 ) undergoing cosmetic surgery procedures performed under general anesthesia (Keck et al., 2010) . In order to limit variables or confounding factors which might affect adipose tissue function, subjects were devoid of metabolic, endocrine, or cardiovascular diseases. The study was approved by local ethics committee, and patients gave their informed consent for using their ADSCs for the present experiments. ADSCs were isolated by collagenase digestion (0.075% collagenase in PBS; Sigma type IA collagenase) as described previously (Zuk et al., 2001) , counted using the Trypan blue dye exclusion assay, and then seeded on plastic tissue culture plates at a density of 4000 cell/cm 2 in DMEM-low glucose medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen/Gibco) and antibiotics (defined as ADSCs growth medium). After achieving a density of 80-90%, cultures were trypsinized and subcultured at a 1:4 ratio. All tests were performed at passage 4.
Immunophenotyping
ADSC populations used in the experiments were analysed with specific cell surface markers to evaluate homogeneity. Cells were harvested with trypsin, centrifuged at 500 g for 5 min, washed with phosphate-buffered saline (PBS), and resuspended in PBS. Cells (1 × 10 5 cells/tube) were then incubated at 4°C for 30 min with the following antibodies: CD29-PE-Cy5, CD90 (Thy-1)-PE-Cy5, CD45-FITC, CD31-PE, CD105 (SH2) and CD73 (SH3/4) (Becton Dickinson). After a second wash with PBS, samples incubated with unconjugated primary antibodies were incubated with anti-mouse-PE secondary antibody (Guava Technologies) for additional 15 min at 4°C. Finally, the cell suspension was washed with PBS, and 10 5 labeled cells were acquired with an EasyCyte Flow cytometer (Guava Technologies). Control samples were incubated with PBS instead of primary antibody, followed by incubation with anti-mouse-PE secondary antibody. All the plots generated were analysed with Guava ExpressPlus software (Guava Technologies).
Adipocyte differentiation and pharmacological treatment
To induce adipocyte differentiation, ADSCs were grown to confluence (defined as day 0) and then cultured in adipogenic induction medium [DMEM high glucose (25 mM) supplemented with 10% FBS, antibiotics, 1 μM dexamethasone (Sigma), 200 μM indomethacin (Sigma), 0.5 mM IBMX (Sigma), and 10 μg/ml insulin (Sigma)] for 14 days, which represents the usual time needed to acquire a fully differentiated phenotype. The influence of the different antipsychotic drugs on adipogenesis was tested by supplementing the differentiation medium with clozapine (Sigma, MO, USA), olanzapine (Toronto Research Chemicals, Toronto, Canada), ziprasodone (Pfizer inc., NY, USA) or haloperidol (Sigma, MO, USA) at different concentrations during the first stage of differentiation (either for the first 3 days or for the first 7 days during differentiation). The antipsychotic drugs were used at doses similar to their therapeutic plasma concentrations [considered to be in the range of 0.6 to 1 μM clozapine (Broich et al., 1998) ; 0.07-0.2 μM olanzapine (Bergemann et al., 2004; Robinson et al., 2006) ; 0.1-0.25 μM ziprasidone (Vogel et al., 2009 ); and 0.05 μM haloperidol (Coryell et al., 1998) ], at doses 10-fold higher than those (10 μM clozapine; 2 μM olanzapine; 2.5 μM ziprasidone; 0.5 μM haloperidol), or at 20, 30, 40 and 100 μM. Control cells were treated with DMSO alone (solvent used to dissolve the drugs) and no effect of this solvent on adipogenesis was observed (data not shown).
Cell viability analysis during adipogenic differentiation
Cells were plated into 12-well cell culture plates (1.5 × 10 4 cells/ well) and grown to confluence (day 0). The cells were then cultured in adipogenic induction medium supplemented with DMSO (control) or clozapine, olanzapine, ziprasidone or haloperidol at different concentrations, as described above. On day 14 after induction, the cells were trypsinized, stained with trypan blue and counted with an Automated Cell Counter (Invitrogen). The experiment was done in triplicates for each antipsychotic treatment and each cell line. The data were normalized to cell number of DMSO-treated samples.
RNA extraction, reverse transcription reactions and quantitative real time PCR
Cells for expression analysis were grown in 75 cm 2 plastic culture flasks. Total RNA from confluent undifferentiated ADSCs (day 0), and from cells cultured in adipogenic induction medium supplemented or not (DMSO alone) with the antipsychotics was isolated using Nucleospin RNA kit (Macherey-Nagel). RNA quality and concentration were accessed respectively by 1.5% agarose gel electrophoresis and Nanodrop ND-1000. Complementary DNA (cDNA) was produced from 1.5 μg of total RNA using Superscript II reverse transcription kit (Invitrogen). Quantitative real-time PCR was performed using approximately 15 ng of cDNA and SYBR Green PCR master mix in an ABI Prism 7500 system (Applied Biosystems). Primers were designed using Primer Express software v2.0 (Applied Biosystems) and the amplification efficiency (E) of each primer was calculated according to the equation E = 10 (− 1 / slope) . The expression data of the adipocytespecific transcripts C/EBPβ, PPARγ2 and LPL, as well as an unrelated transcript DDX58, were determined by relative quantification in comparison to four endogenous controls HMBS, HPRT1, GAPDH and SDHA. GeNorm v3.4 was used to determine the most stable controls and calculate the normalization factors (NF) (Vandesompele et al., 2002) . The expression data is given by the ratio between each transcript ΔΔCt (E ΔCT ) and NF. All cDNA samples were run in triplicates, and the threshold suggested by the instrument software was used to calculate Ct. Results were normalized to DMSO-treated control (1.0).
Oil red O staining and measurement of triglyceride content
Cells for quantitation of lipid accumulation were cultured in 12-well cell culture plates and, for each experiment, three wells per condition were used. For Oil Red O staining, following adipogenic differentiation for 14 days, cells were washed with PBS, fixed in 4% formaldehyde for 30 min and then stained with 0.6% (w/v) Oil Red O solution (60% isopropanol, 40% water) for 1 h at room temperature. Cells were them washed with 60% isopropanol three times to remove unbound dye and photographed. Stained Oil Red O was also eluted with 4% NP-40 in isopropanol (v/v) and quantified by measuring the optical absorbance at 490 nm. Oil Red O staining of undifferentiated ADSCs grown in parallel culture served as the blank sample for this assay.
Cellular triglyceride content was determined by the enzymecolorimetric method, using a commercially available Kit (Laborlab). Results were normalized by the number of cells present in each well and were expressed as percent of control (DMSO).
Cell-proliferation analysis
A concentration of 4000 viable cells/cm 2 was plated to each well of a 12-well cell culture plate in ADSCs growth medium. After 24 h, when total cell adhesion was verified, the medium was changed for ADSCs growth medium supplemented or not with DMSO (control), or clozapine (20 μM, 30 μM), olanzapine (20 μM, 40 μM, 100 μM), and haloperidol (20 μM, 40 μM). The cells were trypsinized at 0, 24, 48 and 72 h after plating, stained with trypan blue and counted using Guava EasyCyte Flow Cytometer (Guava Technologies). The experiment was done in triplicates for each time point and each cell line.
Lipogenesis measurement
Adipocytes from freshly excised abdominal subcutaneous adipose tissue of other 5 health female patients (aged 32-41 years; BMI b 25 kg/m 2 ) undergoing liposuction procedures performed under general anesthesia were isolated by enzymatic digestion (0.075% colagenase type II), suspended in Krebs/Ringer/phosphate buffer (pH 7.4) containing 1% BSA and 2 mM glucose (to a final concentration of 1 × 10 6 cells/mL), and saturated with a gas mixture of CO 2 5%/O 2 95%. Aliquots of 450 μL were then pipetted into polypropylene tubes containing [U-
DMSO or clozapine, olanzapine and haloperidol (40 μM and 100 μM) in the presence and absence of 10 nM insulin for 3 h at 37°C in an orbital shaking water bath. After this period, the incubation medium was acidified with 200 μL of 8N H 2 SO 4 to rupture cells, and 2.5 mL of Dole's reagent (isopropanol : n-heptane : H 2 SO 4 , 4:1:0.25 vol/vol/vol) were added for lipid extraction. Radioactivity in the organic phase was determined by liquid scintillation counting and represented glucose incorporation into lipid. Activities of lipogenesis were normalized to protein concentrations and were expressed as percentage of control (DMSO). Lipogenesis was increased with maximal insulin concentration 1.3 to 1.5 fold (data not shown).
Cell cytotoxicity analysis during lipogenesis measurement (XTTcolorimetric assay)
Antipsychotic-induced cytotoxicity during in vitro lipogenesis was measured by means of a colorimetric XTT viability assay (Cell Proliferation Kit II-XTT, Roche) in accordance with the instructions of the supplier. Briefly, adipocytes from two out of the five female subjects described above were pipetted into microcentrifuge tubes (at a density of 1 × 10 6 cells/tube) and treated as for the lipogenesis experiment. XTT solution was added into each tube to give a final concentration of 0.3 mg/mL, and the cells were then incubated for 3 h at 37°C. After the reaction, resulting formazan dye was quantified with an ELISA plate reader at 450 nM whereas the absorbance correlated directly with the number of viable cells. All incubations were performed in triplicate with inclusion of a positive control (mechanical cell lysis) and a blank sample (containing media, XTT but no cells).
Statistical analysis
Data are reported as the means ± standard deviation (SD). Comparison between culture conditions was determined using Student's t-test, where p b 0.05 was considered statistically significant.
Results
Isolation and characterization of human adipocyte-derived stem cells (ADSCs)
ADSCs were obtained from human abdominal subcutaneous adipose tissue samples (n = 5 female donors) and cultured for four passages. To characterize the homogeneity of the samples, they were subjected to flow cytometric analysis. We observed that these cells expressed the mesenchymal stem cell markers CD105 and CD73, the cell adhesion markers CD29 and CD90, but did not express the hematopoietic cell marker CD45 and the endothelial cell marker CD31 (Fig. 1) . These findings suggest that we have isolated a relatively homogeneous population of mesenchymal cells.
All ADSC samples subjected to adipogenic differentiation showed marked alteration in cell morphology and accumulation of lipid droplets that could be stained by the lipophilic dye Oil Red O, which were completely absent in the undifferentiated cells (Fig. 2) . In addition, real-time PCR analysis revealed that on day 3 of the differentiation process the expression levels of the key adipogenic transcription factors C/EBPβ and PPARγ2 were significantly increased compared to undifferentiated ADSCs (day 0); and that on day 14 after induction the expression levels of PPARγ2 and LPL, an adipocytespecific enzyme related to triglyceride metabolism that appears later on in the differentiation process, were also largely increased compared to undifferentiated ADSCs (Fig. 3) .
Effects of antipsychotic drugs on the viability of ADSCs during adipogenic differentiation
We first examined whether clozapine, olanzapine, ziprasidone or haloperidol at different concentrations exert cytotoxic effects on ADSCs during the adipogenic differentiation protocol. The concentrations used were similar to those detectable in the plasma of treated patients (1 μM clozapine, 0.2 μM olanzapine, 0.2 μM ziprasidone, and 0.05 μM haloperidol), or were 10-fold higher or more (20 to 100 μM) than those. We observed that ziprasidone induced elevated levels of cell death at all concentrations after few hours in culture, and it was not further investigated in our experiments (data not shown). Cell exposure to concentrations higher than 30 μM of clozapine and 40 μM of haloperidol also induced cytotoxicity after 2-3 days in culture. On the other hand, olanzapine at all concentrations tested did not appear to have any effect on cell viability (Fig. 4) . Therefore, concentrations up to 30 μM of clozapine, 100 μM of olanzapine and 40 μM of haloperidol displayed no significant effect on cell viability until the end of the differentiation period and were used in subsequent experiments.
Effects of antipsychotic drugs on the adipocyte differentiation program of ADSCs
We next examined the effects of clozapine, olanzapine and haloperidol on the control of the adipocyte differentiation program. On day 3 of the differentiation process, we observed that administration of these drugs at doses similar to their therapeutic plasma concentrations or at doses 10-fold greater than those displayed no significant effects on the expression of C/EBPβ and PPARγ2. On the other hand, administration of these drugs at higher doses induced a slight dose-dependent increase in the expression of these genes (Fig. 5A) . Similar results were observed on day 14 after induction, in which increases in the expression levels of PPARγ2 and LPL were also observed in a dose-dependent manner but only at higher antipsychotic dosages (Fig. 5B) . As an internal control, no significant change in the expression pattern of a functionally unrelated gene, DDX58, was detected in the presence of the antipsychotic drugs (data not shown). These results indicate that all three antipsychotics at doses higher than their therapeutic plasma concentrations induced a dosedependent increase in adipogenesis-related mRNAs.
Effects of antipsychotics on cellular triglyceride accumulation
To determine whether the observed increase in the expression of adipocyte-related genes was also accompanied by triglyceride B A accumulation, direct triglyceride measurements and Oil Red O staining were performed on day 14 after induction. We observed that triglyceride content of differentiated adipocytes did not change significantly in response to the antipsychotics (Fig. 6 ). In accordance with these results, OD value of Oil Red O eluted solution, which represents lipid droplet accumulation in the cytoplasm, did not increase significantly in the antipsychotic treated samples (data not shown). Therefore, although addition of clozapine (20 and 30 μM), olanzapine (20, 40 and 100 μM) and haloperidol (20 and 40 μM) in the differentiation medium induced a comparable increase in the levels of adipocyte-specific genes, robust increase in intracellular lipid levels compared with control was not observed. In order to verify whether a longer antipsychotic treatment period had implications in the differentiation potential of ADSCs, the antipsychotic drugs (at the same concentrations specified previously) were also added for the first 7 days during differentiation and no differences were observed between treatments (data not shown).
Effects of antipsychotics on proliferation of undifferentiated ADSCs
Effects of clozapine (20 and 30 μM), olanzapine (20, 40 and 100 μM) and haloperidol (20 and 40 μM) exposure on the proliferation rates of ADSCs were also assessed. Under our experimental conditions, whereas DMSO (control) exerted no effects on ADSCs expansion, the three antipsychotic drugs at all concentrations tested exerted inhibitory effects on ADSCs proliferation, observed by a strong decrease in cell number soon after the beginning of antipsychotic treatment (data not shown).
Effects of antipsychotic drugs on lipogenesis in human mature adipocytes
Effects of clozapine, olanzapine and haloperidol on basal and insulin-stimulated lipogenesis were also assessed by measuring incorporation of labeled 14 C-glucose into total lipids. In order to obtain a clearcut effect and to be able to compare our results with those of a previous study using isolated rat adipocytes, the antipsychotics were used at 40 and 100 μM. We first ensured that at these concentrations the antipsychotics did not exert cytotoxic effects on human mature adipocytes. At the end of the experiment, microscopic analysis of the cell suspensions did not reveal any observable cell lysis. In addition, cell viability assessed by the XTTcolorimetric assay indicated that the antipsychotics in these dosages did not induce cytotoxicity during the incubation period used in the experiment (data not shown). We observed, under our experimental conditions, no significant effects of clozapine on basal and insulin-stimulated lipogenesis compared to control (cells treated with DMSO-100%) (Fig. 7) . On the other hand, we observed that olanzapine, at the highest concentration analysed (100 μM), significantly inhibited insulin- stimulated rates of lipogenesis (approximately 14%), whereas haloperidol, at both concentrations, exerted the strongest inhibitory effects on both basal and insulin-stimulated de novo lipogenesis (approximately 15% and 17% at 40 μM and 12% and 24% at 100 μM respectively) (Fig. 7) . Whereas the effects of clozapine and olanzapine on mature adipocytes are not correlated with their greater propensity to induce adiposity, our results clearly suggest that haloperidol reduces both basal and maximal insulin-stimulated rates of lipogenesis in human adipocytes in vitro.
Discussion
A clear understanding of the mechanisms involved in SGA-induced weight gain and metabolic disturbances is of great importance in clinical practice because it can help guide therapeutic decisions as well as the design of new treatments to reduce the serious metabolic side effects of these largely prescribed drugs.
It has recently been proposed that a direct effect of specific SGA on adipose tissue could provide an alternative, but not necessarily exclusive, mechanism for the adverse metabolic outcomes (Hemmrich et al., 2006; Minet-Ringuet et al., 2007; Pavan et al., 2009; Vestri et al., 2006; Victoriano et al., 2010; Yang et al., 2007; . The present study focused on the effects of antipsychotics with different binding profiles and weight gain liabilities on the proliferation and differentiation of ADSCs and lipogenesis in human mature adipocytes in vitro.
Our results showed that the SGA clozapine and olanzapine had slight stimulatory effects on genes considered as early or late markers of adipose tissue differentiation. Our data also showed, for the first time, that haloperidol exhibited similar stimulatory effects on the expression of adipocyte-specific genes. However, these effects were observed to occur only in those cells receiving antipsychotic doses higher than that observed in the plasma of treated patients. Interestingly, the activation of the transcriptional program of adipogenesis in the cells treated with these three antipsychotic drugs was not accompanied by a significant increase in triglyceride (TG) accumulation within differentiated adipocytes. Although the reasons for these alterations in gene expression remain to be determined, our results suggest that the observed increase in expression of the adipocyte-specific genes is not sufficient to induce significant TG accumulation, and that the differing degrees of weight gain upon use of clozapine, olanzapine and haloperidol are not related to different potential of these drugs to induce adipogenesis of progenitor cells present in the adipose tissue.
It is important to note that two previous studies using cultured human adipocyte progenitor cells reported that the addition of clozapine and olanzapine during the initial stages of adipogenic differentiation process induced a small increase in TG accumulation (about 1.3 fold compared to control) within differentiated cells (Hemmrich et al., 2006; Pavan et al., 2009 ). Whereas, Hemmrich et al. (2006) used similar concentrations of clozapine to those we used, Pavan et al. (2009) used a much higher concentration of clozapine and olanzapine. Thus, despite the methodological differences, the studies performed so far suggest that clozapine and olanzapine did not potently increase adipogenesis of human adipocyte precursor cells, even at very high dosages. In addition, our findings suggest that enhanced proliferation of human ADSCs may also not be an important mechanism by which the SGA alter adipose tissue biology.
Regarding the effects of the antipsychotics on human mature adipocytes, our data revealed that whereas the SGA clozapine did not exert any significant effect on the rates of lipogenesis in isolated human adipocytes, olanzapine significantly inhibited insulin-stimulated lipogenesis at the highest concentration used. These results suggests that the effects of olanzapine on central nervous system pathways involved in regulation of energy balance and adiposity might overcame its possible direct inhibitory effect on the lipogenic capacity of human adipocytes. It is noteworthy that Vestri et al. (2006) , after execution of a protocol very similar to the one we used, observed that clozapine and olanzapine (100 μM) enhanced both basal and insulin-induced lipogenesis in isolated rat adipocytes. Therefore, these findings suggest that the SGA might show speciesspecific effects, and this point should be taken into consideration in studying their adverse effects. Interestingly, we observed that haloperidol exerted the strongest inhibitory effects on both basal and insulin-stimulated rates of lipogenesis in isolated human adipocytes. Therefore, although further investigations are required to determine the clinical relevance of these findings, it is tempting to speculate that the haloperidol-induced reduction in lipogenic capacity of human adipose tissue may be a mechanism contributing to its lower propensity to induce weight gain and metabolic abnormalities.
Conclusions
Taken together, the results obtained from the experiments conducted with these in vitro models suggest that a potent and direct effect of clozapine and olanzapine on adipose tissue development and metabolism is not an important mechanism by which these SGA induce metabolic disturbances in humans. We cannot rule out that these SGA have different effects on visceral adipose tissue, which is known to exhibit different biological properties compared to subcutaneous adipose tissue. In addition, our findings also point to a possible mechanism contributing to haloperidol's lower liability to cause weight gain in humans, via inhibition of the lipogenic capacity of adipocytes. Finally, our data suggest that, due to species related differences, the use of cells derived from human adipose tissue represents a more biologically relevant model than murine cells for studying the effects of antipsychotic drugs on this tissue. It will be a major challenge to investigate in vivo the exact effects of these antipsychotic drugs on human adipose tissue development and metabolism.
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